Hagens Berman tells ADMA investors to contact firm before Aug. 10 deadline
Hagens Berman says a securities fraud class action has been filed against ADMA Biologics over alleged misstatements about financial condition, revenue recognition and inventory distribution.
Hagens Berman said on Aug. 9, 2026, that investors in ADMA Biologics, Inc. should contact the firm before an Aug. 10 deadline tied to a securities fraud class action over the company’s financial reporting and business practices.
In its alert, the firm said the complaint alleges investors were misled about ADMA’s financial condition, revenue recognition and inventory distribution. It said those alleged misstatements later came to light through corrective disclosures that wiped out shareholder value.
The alert says the lawsuit claims defendants artificially inflated the stock by misrepresenting and failing to disclose facts about the company’s operations. It points to a Culper Research short-seller report that alleged channel stuffing, rebates and an undisclosed related-party distributor called Genesis BioPharma. The alert says that report triggered sell-offs over two trading days.
ADMA responded in a press release that it was “taking appropriate steps to review the assertions,” according to the alert, which also says Cantor Fitzgerald downgraded the stock. The firm said those developments further hurt investor confidence.
Reed Kathrein, a Hagens Berman partner leading the firm’s investigation, said the firm was examining whether ADMA made false and misleading statements that concealed the reality of its distribution channels and financial reporting, according to the alert.
Hagens Berman said investors with substantial losses, or people with information that could help the investigation, may contact the firm. The alert also says whistleblowers who provide original information may be eligible for SEC whistleblower rewards of up to 30 percent of any successful recovery made by the SEC.
The firm identified ADMA Biologics as a public company listed on Nasdaq under the ticker ADMA. The alert was published by PR Newswire on Aug. 9, 2026.
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()